Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets

British Journal of Pharmacology

Volumn 154, Issue 4, 2008, Pages 787-796

  Toque, H A ^a   Teixeira, C E ^a   Priviero, F B M ^a   Morganti, R P ^a   Antunes, E ^a   De Nucci, G ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Calcium blockade; cGMP; Endothelium; NO; PDE5 inhibitors; Pulmonary artery; Relaxation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CALCIUM CHANNEL; CALCIUM CHLORIDE; CAPTOPRIL; CYCLIC GMP; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; TEZOSENTAN; THROMBIN; VARDENAFIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL REACTIVITY; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RABBIT; THROMBOCYTE; VASODILATATION;

ANIMALS; BLOOD PLATELETS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CARBOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; IMIDAZOLES; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY ARTERY; PURINES; RABBITS; SULFONES; TRIAZINES; VASODILATION;

EID: 44949156264     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.141     Document Type: Article

References (36)

1. Ambudkar IS (2007). TRPC1: a core component of store-operated calcium channels. Biochem Soc Trans 35: 96-100.
2. Authi KS (2007). TRP channels in platelet function. Handb Exp Pharmacol 179: 425-443.
3. Bender AT, Beavo JA (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
4. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH et al. (2004). Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66: 144-152.
5. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM et al. (1996). Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8: 47-52.
6. Carson CC, Lue TF (2005). Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Intern 96: 257-280.
7. Fleckenstein A, Fleckenstein-Grün G (1988). Mechanism of action of calcium antagonists in heart and vascular smooth muscle. Eur Heart J 9 (Suppl H): 95-99.
8. Furchgott RF, Vanhoutte PM (1989). Endothelium-derived relaxing and contracting factors. FASEB J 9: 2007-2018.
9. Ghofrani HA, Grimminger F (2006). Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors. Dtsch Med Wochenschr 131: S311-S314.
10. Ghofrani HA, Olschewski H, Seeger W, Grimminger F (2002b). Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure. Pneumologie 56: 665-672.
11. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N et al. (2002a). Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360: 895-900.
12. Giordano D, De Stefano ME, Citro G, Modica A, Giorgi M (2001). Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme aminoterminal domain. Biochem Biophys Acta 1539: 16-27.
13. Godfraind T (1988). Calcium channels in smooth muscle. Ann NY Acad Sci 522: 312-327.
14. Hanson KA, Burns F, Rybalkin SD, Miller JW, Beavo J, Clarke WR (1998). Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 158: 279-288.
15. Kuriyama H, Kitamura K, Nabata H (1995). Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Pharmacol Rev 47: 387-573.
16. 2+ release and entry during contraction elicited by norepinephrine in rat resistance arteries. Am J Physiol 276: H300-H308.
17. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR et al. (2003). Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 64: 533-546.
18. Montorsi F, Briganti A, Salonia A, Montorsi P, Rigatti P (2004). The use of phosphodiesterase type 5 inhibitors for erectile dysfunction. Curr Opin Urol 14: 357-359.
19. Motulsky HJ, Snavely MD, Hughes RJ, Insel PA (1983). Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors. Circ Res 52: 226-231.
20. Murad F (1988). Role of cyclic GMP in the mechanism of action of nitrovasodilators, endothelium-dependent agents and atrial natriuretic peptide. Biochem Soc Trans 16: 490-492.
21. 2+ channels in the regulation of the pulmonary circulation: potential role of caveolae and implications for high altitude pulmonary edema. Respir Physiol Neurobiol 151: 192-208.
22. Oshima T, Ozono R, Yano Y, Higashi Y, Teragawa H, Miho N et al. (2005). Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Hypertens Res 28: 889-894.
23. Palés J, Palacios-Araus L, López A, Gual A (1991). Effects of dihydropyridines and inorganic calcium blockers on aggregation and on intracellular free calcium in platelets. Biochim Biophys Acta 1064: 169-174.
24. 2+ influx and endothelial permeability. Am J Physiol Lung Cell Mol Physiol 287: L1303-L1313.
25. 2 synthesis in human platelets. Eur J Pharmacol 132: 309-312.
26. Priviero FMB, Teixeira CE, Toque HA, Claudino MA, Webb RC, De Nucci G et al. (2006). Vasorelaxing effects of propranolol in rat aorta and mesenteric artery: a role for nitric oxide and calcium entry blockade. Clin Exp Pharmacol Physiol 33: 448-455.
27. Rink TJ, Sage SO (1990). Calcium signaling in human platelets. Annu Rev Physiol 52: 431-449.
28. Rosen RC, Kostis JB (2003). Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 92: 9M-18M.
29. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003). Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93: 280-291.
30. Sage SO (1997). The Wellcome Prize Lecture. Calcium entry mechanisms in human platelets. Exp Physiol 82: 807-823.
31. Thusu KG, Morin FC, Russell JA, Steinhorn RH (1995). The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am J Respir Crit Care Med 152: 1605-1610.
32. Tsai BM, Wang M, Pitcher JM, Kher A, Brown JW, Meldrum DR (2005). Endothelium-dependent pulmonary artery vasorelaxation is dysfunctional in males but not females after acute lung injury. Surgery 138: 78-84.
33. Vogalis F, Publicover NG, Hume JR, Sanders KM (1991). Relationship between calcium current and cytosolic calcium in canine gastric smooth muscle cells. Am J Physiol 260: C1012-C1018.
34. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J et al. (2006). EAU Guidelines on erectile dysfunction: an update. Eur Urol 49: 806-815.
35. Wilkens H, Guth A, König J, Forestier N, Cremers B, Hennen B et al. (2001). Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104: 1218-1222.
36. Ziegler JW, Ivy DD, Wiggins JW, Kinsella JP, Clarke WR, Abman SH (1998). Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med 158: 1388-1395.